CPAY
Corpay, Inc.
CPAY's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over CPAY overall, supported by stronger valuation and stronger modeled upside.
CPAY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Stable |
CPAY's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
CPAY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $456 | — |
| Cheap | 19x | $352 | -23% |
| Fair | 23x | $413 | -9.5% |
| Current | 25x | $456 | — |
| Expensive | 28x | $518 | +14% |
Historical ranges are pointers, not guarantees.
CPAY's PE is in its expensive range at 25x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over CPAY in the historical PE scenario, which offers more potential upside but is not a forecast.
CPAY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
CPAY has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
CPAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $31.05 | +71% |
| Q3 2026 | $18.17 | +23% |
| Q2 2026 | $16.42 | +12% |
| Q1 2026 | $16.70 | +17% |
| Q4 2025 | $15.03 | +7.6% |
| Q3 2025 | $14.72 | +5% |
| Q2 2025 | $14.71 | +6.9% |
| Q1 2025 | $14.25 | +6% |
| Q4 2024 | $13.97 | +5.8% |
CPAY's earnings per share have climbed steadily: $18.17 over the past year, up 23% from the year before, and higher year over year for 22 quarters in a row.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over CPAY on earnings, with stronger typical year-over-year growth.
CPAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +18% |
| Q2 2026 | $1.3B | +21% |
| Q1 2026 | $1.3B | +25% |
| Q4 2025 | $1.2B | +21% |
| Q3 2025 | $1.2B | +14% |
| Q2 2025 | $1.1B | +13% |
| Q1 2025 | $1B | +7.5% |
| Q4 2024 | $1B | +10% |
CPAY's revenue has grown year over year for 22 quarters in a row: $1.4B last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 45% | +0.3 points |
| Q2 2026 | 35% | -8.2 points |
| Q1 2026 | 50% | +8 points |
| Q4 2025 | 45% | -2 points |
| Q3 2025 | 45% | -0.9 points |
| Q2 2025 | 44% | -0.9 points |
| Q1 2025 | 42% | 0 points |
| Q4 2024 | 47% | +2 points |
CPAY's operating margin was 45% last quarter, about level with the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over CPAY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over CPAY on profitability, with a higher operating margin.
CPAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$735M | -$305.2M |
| Q2 2026 | $1.4B | +30% |
| Q1 2026 | -$107.7M | +$11.2M |
| Q4 2025 | $760.3M | +26% |
| Q3 2025 | -$429.8M | -221% |
| Q2 2025 | $1.1B | +119% |
| Q1 2025 | -$118.9M | -138% |
| Q4 2024 | $604.6M | -11% |
CPAY usually generates cash, though not every quarter: the latest was −$735M, but it generated $1.3B over the past year.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over CPAY on cash flow, with more consistent year-over-year improvement.
CPAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +60K shares |
| 1 year | -6.7% | -4.7M shares |
| 3 years | -11% | -8.2M shares |
| 5 years | -21% | -17.3M shares |
| Available history | -27% | -24M shares |
CPAY has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $706.5M |
| Q2 2026 | $326.6M |
| Q1 2026 | $786M |
| Q4 2025 | $500.2M |
| Q3 2025 | $191.7M |
| Q2 2025 | $32.2M |
| Q1 2025 | $58.7M |
| Q4 2024 | $248.8M |
CPAY spent $2.3B buying back its own shares over the past year, about four times what it spent the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
CPAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Moderate |
| Q2 2026 | 2.8x | Moderate |
| Q1 2026 | 3.0x | Moderate |
| Q4 2025 | 3.2x | Elevated |
| Q3 2025 | 2.7x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.0x | Elevated |
| Q4 2024 | 3.0x | Elevated |
CPAY's net debt is about 3.0 years of its operating earnings (EBITDA), up from 2.7 years a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over CPAY on leverage, with a lower net debt burden relative to earnings.
CPAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 72.0 | Overbought |
| Stochastic | 66.5 | Neutral |
CPAY's weekly RSI is 72 (overbought) and its Stochastic is 67 (neutral).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
CPAY PE vs Technology Sector
| Metric | CPAY | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 28x | 9.9% below |
| PE % | 70 | 35 | 35 pts above |
CPAY is trading at 25x earnings, in line with the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over CPAY on valuation relative to its sector.
CPAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $413.9 | 10% above |
| 20 week MA | $399.7 | 14% above |
| 50 week MA | $354.3 | 29% above |
| 100 week MA | $339.4 | 34% above |
| 200 week MA | $304.8 | 50% above |
CPAY has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
CPAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $285.8 | $270.5 | -5.4% |
| 2021 | $270.5 | $223.7 | -17% |
| 2022 | $223.7 | $181.2 | -19% |
| 2023 | $181.2 | $282.6 | +56% |
| 2024 | $282.6 | $341.2 | +21% |
| 2025 | $341.2 | $310.2 | -9.1% |
| 2026 YTD | $310.2 | $456.0 | +47% |
CPAY has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.